This shift in focus away from AstraZeneca to the Pfizer vaccine has serious impacts on the timing of the rollout and public confidence in the AstraZeneca vaccine.
Academic rigour, journalistic flair
Articles on AstraZeneca
Displaying 1 - 20 of 63 articles
Kenya grapples with two major challenges in the vaccination rollout: access to sufficient doses in light of the global shortage; and vaccine hesitancy.
The vaccine rollout was thrown into fresh uncertainty on Thursday night after the government received medical advice against using the AstraZeneca vaccine for people under 50 because of the very small risk of blood clots.
Stephen Duckett on what’s wrong with the rollout.
Michelle Grattan discusses the vaccine rollout with Stephen Duckett.
Good news for children and young people, bad news for Johnson & Johnson.
These mistakes have been mainly caused by our leaders giving priority to a good political story over good policy.
The UK says its contract is better – it simply put tougher penalty clauses in place.
AstraZeneca just announced results from its US-based trial. It found the vaccine to be 79% effective and safe for use, despite recent concerns around reports of blood clots.
Underlying medicines 'do no harm' principle is a deeper claim that it is worse to do harm than to allow harm to happen.
Supply chain issues can be addressed – but the issues with the AstraZeneca vaccine are political, too.
The European Medicines Agency has said the Oxford/AstraZeneca vaccine is not associated with an increased overall risk of developing blood clots.
It's not too late for Australia to repair our vaccine strategy, though we will never make up for the months lost.
The government is gifting 8,000 doses of COVID-19 vaccines to Papua New Guinea for frontline health workers, and is requesting an additional 1,000,000 doses from European authorities for the pacific nation.
Blood clots form to prevent blood loss both inside and outside the body. But they can become dangerous if they get dislodged from where they form.
Data from clinical trials and the real world COVID vaccine rollout suggest blood clots occur no more frequently in vaccinated people than they do in the general population.
Italy's decision to block export of AstraZeneca vaccines to Australia will likely not impact our vaccine roll-out. But vaccine scarcity is a looming problem in other parts of the world.
The Oxford/AstraZeneca vaccine is the second COVID shot to be approved in Australia, and it's likely Australians will start receiving it next month.
Australia should pivot to a high-efficacy vaccine like Pfizer or Novavax to give us the best chance of achieving herd immunity.
The Oxford/AstraZeneca vaccine is the latest to struggle against the South African variant in trials, while in Israel vaccines may be beginning to have an effect.
Over 130 million doses have already been administered worldwide. It's early days, but the signs are promising in places like Israel and the UK.
Top contributors
-
Professorial Fellow, University of Canberra
-
Director of the Digital Health Enterprise Zone (DHEZ), University of Bradford, Reader in Health Service Operations, University of Bradford
-
Professor of Immunology, RMIT University
-
Senior Lecturer in Evidence-Based Healthcare and University Ethics Advisor, University of Portsmouth
-
Principal Lecturer, Microbiology and Biomedical Science Practice, Fellow of the Institute of Biomedical Science, University of Brighton
-
Project Coordinator & Staff Scientist, Vanderbilt University Medical Center, Vanderbilt University
-
Professor of Medicine, University of East Anglia
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Senior Lecturer in Supply Chain Management, Liverpool John Moores University
-
Postdoctoral Research Fellow, RMIT University
-
Professor of Intellectual Property Law, Queen Mary University of London
-
Associate Professor, Murdoch Children's Research Institute
-
Professor of Child Health Informatics, Department of Paediatrics, The University of Melbourne
-
Associate professor, La Trobe University
-
Emeritus Professor of Accounting, University of Essex, University of Essex
